<< Back
Mark Goldberg, M.D.

Mark Goldberg was appointed a member of Idera’s Board of Directors in January 2014. Dr. Goldberg has also served as a member of the board of directors of ImmunoGen since 2011, a member of the board of directors of GlycoMimetics since 2014, a member of the board of directors of Blueprint Medicines Corporation since 2015, and a member of the board of directors of Avacta Group since 2021. In addition, he is a member of the board of directors of the American Cancer Society, a non-profit organization.

Dr. Goldberg previously served on the boards of directors of Audentes Therapeutics from 2017 until 2020 and aTyr Pharma from 2015 until 2017. He also served in several capacities with Synageva BioPharma from 2011 until 2015, including as an advisor and medical and regulatory strategist, Executive Vice President for Medical and Regulatory Strategy, and Senior Vice President of Medical and Regulatory Affairs. Dr. Goldberg also previously served in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President for Clinical Development and Therapeutic Group Head for Oncology and Personalized Genetic Health. He was also the Chairman of Genzyme’s Early Product Review Board. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme®, and Lumizyme®. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute. He was also an Associate Professor of Medicine at Harvard Medical School from 1996 until 2021 and is currently a lecturer and part-time faculty at Harvard Medical School.

Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. He holds an A.B. from Harvard College and an M.D. from Harvard Medical School.